Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
29 sept. 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsichtlich des pädiatrischen Prüfkonzepts für B-VEC bei der Behandlung von dystropher Epidermolysis bullosa
22 sept. 2022 18h32 HE
|
Krystal Biotech, Inc.
• Das Unternehmen befindet sich im Zeitplan, um im vierten Quartal 2022 einen Zulassungsantrag für Europa zu stellen • Es sind keine weiteren Studien erforderlich PITTSBURGH, Sept. 23, 2022...
Krystal Biotech reçoit un avis positif de la part du Comité pédiatrique de l'EMA pour son plan d'investigation pédiatrique sur B-VEC pour le traitement de l'épidermolyse bulleuse dystrophique
22 sept. 2022 18h32 HE
|
Krystal Biotech, Inc.
• La Société est sur la bonne voie pour soumettre sa demande de mise sur le marché européen au 4e trimestre 2022 • Aucune étude supplémentaire n'est requise PITTSBURGH, 23 sept. 2022 (GLOBE...
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
21 sept. 2022 16h30 HE
|
Krystal Biotech, Inc.
• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”)...
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
18 août 2022 17h00 HE
|
Krystal Biotech, Inc.
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 ...
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
08 août 2022 07h00 HE
|
Krystal Biotech, Inc.
Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in...
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
01 août 2022 18h39 HE
|
Krystal Biotech, Inc.
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE...
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
01 août 2022 07h00 HE
|
Krystal Biotech, Inc.
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE...
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
06 juil. 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...